Relation between osteocalcin and the energy metabolism in obesity

Stanislava  Nikolić; Nikola Ćurić; Branislava Ilinčić; Zoran Stošić; Dragana Tomić-Naglić; Damir Benc

doi:10.2298/VSP170328085N

Stanislava Nikolić Clinical center of Vojvodina,SerbiaMedical Faculty, University of Novi Sad, Serbia
Nikola Ćurić
Branislava Ilinčić
Zoran Stošić
Dragana Tomić-Naglić
Damir Benc

DOI: https://doi.org/10.2298/VSP170328085N

Keywords: obesity, insulin resistance, osteocalcin, pancreas, body mass index

Abstract

Abstract

Background/Aim. Numerous findings have indicated the potential relation between the osteocalcin, the traditional parameter of bone turnover and the regulation of energy metabolism. The aim of this study was to identify the relationship between osteocalcin and calculated indexes, which evaluate insulin sensitivity, insulin resistance and/or secretory capacity of the pancreas, in non-diabetic, obese subjects. Methods. The study included 57 (11 men and 46 women) euglycemic, obese patients (the body mass index – BMI : 41.03 ± 6.61 kg/m²) and 48 healthy individuals, age and sex matched (BMI : 23.15 ± 2.04 kg/m²). Plasma glucose and the insulin levels during the two-hour oral glucose tolerance test (OGTT) were determined in order to calculate the Homeostatic Model Assessment (HOMA) indexes (HOMA-IR, HOMA-B%), EISI (estimated insulin sensitivity index), EFP (estimated first phase) and ESP (estimated second phase). Osteocalcin was measured by using the Electro-chemiluminescence (ECLIA) methodology. Results. Statistically lower osteocalcin was found in the obese subjects (24.72 ± 9.80 vs 33.31 ± 10.89 ng/mL; p < 0.01). Тhere was a statistically significant positive correlation between osteocalcin and EISI (r = 0.340; p < 0.01). The inverse correlations were found between the osteocalcin and HOMA-IR (r = -0.276; p < 0.01), HOMA-B% (r = -0.337; p < 0.01), EFP (r = -0.332; p < 0.01) and ESP (r = -0.266; p < 0.01). Multiple regression showed that the BMI and osteocalcin have a significant inverse prediction with the EISI and HOMA-IR, but the level of prediction of the BMI was substantially higher. Conclusion. The effect of osteocalcin in the glycoregulation is evident, but its contribution is significantly smaller in relation to other obesity associated factors. Therefore, when assessing its position and the role in glycemic control it is always necessary to bear in mind that osteocalcin represents only one of the many contributing factors, some of which exhibit dominant influence than osteocalcin itself.

References

REFERENCES

Lebovitz HE. Insulin resistance: Definition and consequences. Exp Clin Endocrinol Diabetes 2001; 109 Suppl 2: S135‒48.

Ionescu-Tirgoviste C, Ioacara S, Guja C, Sabau S, Lichiardopol R, Mi¬hai A, et al. A pathophysiological approach to metabolic syn¬drome using factor analysis in an adult Romanian popula-tion. Arch Physiol Biochem 2006; 112(3): 182‒8.

Fukumoto AS, Martin J. Bone as an endocrine organ. Trend En-docrinol Metab 2009; 20(5): 230‒6.

Lee NK, Karsenty G. Reciprocal regulation of bone and energy metabolism. Trend Endocrinol Metab 2008; 19(5): 161‒6.

Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007; 130(3): 456‒69.

Karsenty G. Convergence between bone and energy homeosta-ses: leptin regulation of bone mass. Cell Metab 2006; 4(5): 341‒8.

Cvijovic G, Micić G, Kendereški A, Zoric S, Polovina S, Šumarac DM, et al. Glucose and bone metabolism – potential interac-tions. Acta Clin 2014; 14(3): 68‒72. (Serbian)

Motyl KJ, McCabe LR, Schwartz AV. Bone and glucose metabo-lism: A two-way street. Arch Biochem Biophys 2010; 503(1): 2‒10.

Wiecek A, Adamczak M, Chudek J. Adiponectin: an adipokine with unique metabolic properties. Nephrol Dial Transplant 2007; 22(4): 981‒8.

Aoki A, Muneyuki T, Yoshida M, Munakata H, Ishikawa SE, Suga¬wara H, et al. Circulating osteocalcin is increased in early-stage diabetes. Diabetes Res Clin Pract 2011; 92(2): 181‒6.

Caballero B. The global epidemic of obesity: an overview. Epi-de¬miol Rev 2007; 29: 1‒5.

Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Järvinen H, Van HT, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000; 23(3): 295‒301.

HOMA calculator software. Available from: https://www.dtu.ox.ac.uk/homacalculator/

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28(7): 412‒9.

Hardy OT, Czech MP, Corvera S. What causes the insulin resis-tance underlying obesity. Curr Opin Endocrinol Diabetes Ob-es 2012; 19(2): 81‒7.

Cifuentes M, Johnson MA, Lewis RD, Heymsfield SB, Chowdhury HA, Modlesky CM, et al. Bone turnover and body weight rela-tionships differ in normal weight compared to with havier postmenopausal women. Osteporosis Int 2003; 14: 116‒22.

Lucey AJ, Pashos GK, Thorsdottir I, Martinez JA, Cashman KD, Kiely M. Young overweight and obese women with lower cir-culating osteocalcin concentrations exibit higher insulin resis-tance and concentrations of c-reactive protein. Nutr Res 2013; 33(1): 67‒75.

Matthaei S, Stumvoll M, Kellerer M, Häring HU. Pathophysi-ology and pharmacological treatment of insulin resistance. Endocr Rev 2000; 21(6): 585‒618.

Sarkar PD, Choudhury AB. Relationships between serum osteo-calcin levels versus blood glucose, insulin resistance and mark-ers of systemic inflammation in central Indian type 2 diabetic patients. Eur Rev Med Pharmacol Sci 2013; 17(12): 1631‒5.

Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insu¬lin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sec-tional study in Malmö, Sweden. Diabet Med 2000; 17(4): 299‒307.

Saleem U, Mosley TH, Kullo IJ. Serum osteocalcin is associated with measures of insulin resistance, adipokine levels and the presence of metabolic syndrome. Arterioscler Thromb Vasc Biol 2010; 30(7): 1474‒8.

Yamamuchi T, Kamon J, Ito Y, Tsuchida A, Yokomiyo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423(6941): 762‒9.

Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differen-tially regulates bet cell and adipocyte gene expression and af-fects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA 2008; 105(13): 5266‒70.

Kanazawa I, Yamaguchi T, Tada Y, Yamauchi M, Yano S, Sugimoto T. Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes. Bone 2011; 48(4): 720‒5.

Kanazawa I. Osteocalcin as a hormone regulating glucose me-tabolism. World J Diabet 2015; 6(18): 1345‒54.